NEW YORK, September 22, 2017 /PRNewswire/ --
If you want a Stock Review on IMUC, PLX, SYN, or ABEO then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com shifts focus on the Biotech space, which harnesses cellular and biomolecular processes to develop technologies and products that
Shares in Calabasas, California-based ImmunoCellular Therapeutics Ltd saw a decline of 3.91%, ending Thursday's trading session at $0.33. The stock recorded a trading volume of 1.64 million shares. The Company's shares are trading 16.24% below their 50-day moving average. Moreover, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of various cancers, have a Relative Strength Index (RSI) of 52.60.
On August 23rd, 2017, ImmunoCellular Therapeutics announced that the Company plans to continue strategies to refocus and reallocate its available resources on its promising Stem-to-T-Cell research program. The Stem-to-T-Cell program is designed to provide a novel method of harnessing the immune system to manufacture antigen-specific killer T cells that target and destroy cancer cells and provide long-term immuno-surveillance against tumor recurrence. The Stem-to-T-Cell platform has the potential to address many types of cancer, including both solid and hematological tumors. Visit us today and access your complete report on IMUC for free at:
Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock dropped 3.75%, closing the day at $0.59 with a total trading volume of 218,036 shares. The Company's shares have advanced 13.50% in the past month and 32.63% since the start of this year. The stock is trading 6.32% below its 50-day moving average. Additionally, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 47.38. The complimentary research report on PLX can be accessed at:
On Thursday, shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 1.80 million shares, which was above their three months average volume of 1.57 million shares. The stock ended the day 0.29% higher at $0.96. The Company's shares have surged 55.97% in the past month, 35.30% in the previous three months, and 26.25% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 51.86% and 41.60%, respectively. Furthermore, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have an RSI of 72.30.
On September 12th, 2017, Synthetic Biologics announced the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. The Company intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate. Register for free on DailyStockTracker.com and download the research report on SYN at:
Dallas, Texas-based Abeona Therapeutics Inc.'s stock declined 1.82%, finishing yesterday's session at $16.20 with a total trading volume of 920,681 shares. The Company's shares have skyrocketed 106.37% in the last one month, 189.29% in the previous three months, and 234.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 55.92% and 144.22%, respectively. Additionally, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 70.04.
On August 29th, 2017, Abeona Therapeutics announced that the US FDA has granted Breakthrough Therapy designation status to the Company's EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. The designation from the FDA enables collaborative discussions with senior FDA personnel, priority review, and an expedited approval process to drug candidates where preliminary clinical trials indicate that a therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.
On September 15th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $23 per share. Get free access to your research report on ABEO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...
Sweet's syndrome or acute febrile neutrophilic dermatosis is a skin disorder with no specific ...View All